vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Outdoor Holding Co (POWW). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.4M, roughly 1.4× Outdoor Holding Co). Outdoor Holding Co runs the higher net margin — 16.7% vs -0.8%, a 17.5% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -54.1%). Outdoor Holding Co produced more free cash flow last quarter ($5.0M vs $-15.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Vista Outdoor Inc. was an American designer, manufacturer, and marketer that operated in two segments: shooting sports and outdoor products. It was a "house of brands" with more than 40 labels and subsidiaries.
CTMX vs POWW — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.4M |
| Net Profit | $-154.0K | $2.2M |
| Gross Margin | — | 87.1% |
| Operating Margin | -6.9% | 14.7% |
| Net Margin | -0.8% | 16.7% |
| Revenue YoY | -25.7% | -54.1% |
| Net Profit YoY | 97.6% | 108.5% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.4M | ||
| Q3 25 | — | $12.0M | ||
| Q2 25 | $18.7M | $11.9M | ||
| Q1 25 | $50.9M | $12.6M | ||
| Q4 24 | $38.1M | $12.5M | ||
| Q3 24 | $33.4M | $12.0M | ||
| Q2 24 | $25.1M | $12.3M | ||
| Q1 24 | $41.5M | $-50.7M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | $-154.0K | $-6.5M | ||
| Q1 25 | $23.5M | $-77.5M | ||
| Q4 24 | $18.9M | $-26.1M | ||
| Q3 24 | $5.7M | $-12.4M | ||
| Q2 24 | $-6.5M | $-14.8M | ||
| Q1 24 | $13.8M | $-5.2M |
| Q4 25 | — | 87.1% | ||
| Q3 25 | — | 87.1% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 87.5% | ||
| Q4 24 | — | 87.4% | ||
| Q3 24 | — | 86.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 14.7% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | -6.9% | -50.7% | ||
| Q1 25 | 44.4% | -213.6% | ||
| Q4 24 | 46.4% | -163.8% | ||
| Q3 24 | 12.3% | -50.3% | ||
| Q2 24 | -33.7% | -50.8% | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 16.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | -0.8% | -54.5% | ||
| Q1 25 | 46.2% | -614.5% | ||
| Q4 24 | 49.6% | -208.7% | ||
| Q3 24 | 17.2% | -103.7% | ||
| Q2 24 | -26.0% | -120.2% | ||
| Q1 24 | 33.3% | 10.3% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.67 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $69.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $237.3M |
| Total Assets | $175.1M | $271.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $69.9M | ||
| Q3 25 | — | $65.7M | ||
| Q2 25 | $49.0M | $63.4M | ||
| Q1 25 | $47.6M | $30.2M | ||
| Q4 24 | $38.1M | $31.9M | ||
| Q3 24 | $40.6M | $33.5M | ||
| Q2 24 | $43.2M | $50.8M | ||
| Q1 24 | $36.2M | $55.6M |
| Q4 25 | — | $237.3M | ||
| Q3 25 | — | $235.4M | ||
| Q2 25 | $119.9M | $222.5M | ||
| Q1 25 | $25.0M | $222.0M | ||
| Q4 24 | $-456.0K | $299.6M | ||
| Q3 24 | $-23.5M | $325.6M | ||
| Q2 24 | $-31.2M | $342.5M | ||
| Q1 24 | $-31.7M | $358.0M |
| Q4 25 | — | $271.7M | ||
| Q3 25 | — | $270.3M | ||
| Q2 25 | $175.1M | $269.5M | ||
| Q1 25 | $98.5M | $297.3M | ||
| Q4 24 | $120.5M | $355.4M | ||
| Q3 24 | $139.0M | $368.9M | ||
| Q2 24 | $159.2M | $398.6M | ||
| Q1 24 | $184.7M | $403.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $5.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $5.0M |
| FCF MarginFCF / Revenue | -84.6% | 37.6% |
| Capex IntensityCapex / Revenue | 0.1% | 4.8% |
| Cash ConversionOCF / Net Profit | — | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-2.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | $-15.8M | $-6.7M | ||
| Q1 25 | $-21.0M | $-1.5M | ||
| Q4 24 | $-19.9M | $1.3M | ||
| Q3 24 | $-20.7M | $-9.3M | ||
| Q2 24 | $-19.5M | $-547.5K | ||
| Q1 24 | $-26.0M | $4.3M |
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $-15.8M | $-7.6M | ||
| Q1 25 | $-21.2M | $-2.3M | ||
| Q4 24 | $-20.0M | $720.3K | ||
| Q3 24 | $-20.7M | $-10.6M | ||
| Q2 24 | $-19.6M | $-1.3M | ||
| Q1 24 | $-26.2M | $1.4M |
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | -84.6% | -63.8% | ||
| Q1 25 | -41.6% | -18.6% | ||
| Q4 24 | -52.5% | 5.8% | ||
| Q3 24 | -62.1% | -88.3% | ||
| Q2 24 | -78.2% | -11.0% | ||
| Q1 24 | -63.1% | -2.8% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | 0.1% | 7.5% | ||
| Q1 25 | 0.2% | 6.5% | ||
| Q4 24 | 0.2% | 4.4% | ||
| Q3 24 | 0.1% | 10.4% | ||
| Q2 24 | 0.4% | 6.5% | ||
| Q1 24 | 0.3% | -5.7% |
| Q4 25 | — | 2.55× | ||
| Q3 25 | — | 2.29× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
POWW
Segment breakdown not available.
